Literature DB >> 15639340

Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity.

Yoshiaki Miura1, Shumpei Ohnami, Kimiko Yoshida, Masaki Ohashi, Masaru Nakano, Sumiko Ohnami, Munehisa Fukuhara, Ken Yanagi, Akira Matsushita, Eiji Uchida, Masahiro Asaka, Teruhiko Yoshida, Kazunori Aoki.   

Abstract

We examined the antitumor effect and safety of the adenovirus-mediated expression of antisense K-ras RNA in two peritoneal dissemination models of pancreatic cancer. First, we found that the infection of an adenovirus vector expressing antisense human K-ras RNA (AxCA-AS) induced significant apoptosis in vitro in human pancreatic cancer cells with K-ras mutation. Second, the intraperitoneal (ip) injection of AxCA-AS effectively suppressed the growth of human pancreatic cancer cells in the peritoneal cavity of nude mice. Third, in the hamster syngeneic peritoneal dissemination model, the ip injection of an adenovirus expressing antisense hamster K-ras RNA significantly suppressed the peritoneal growth of hamster pancreatic cancer cells, and no significant systemic toxicity was observed in the treated hamsters. This study suggests a feasibility of the development of a therapeutic strategy against pancreatic cancer based on the adenovirus-mediated transduction of an antisense K-ras construct.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639340     DOI: 10.1016/j.canlet.2004.08.015

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  9 in total

1.  Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer.

Authors:  Shuang Li; Qingzhu Wei; Qin Li; Bin Zhang; Qiang Xiao
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

2.  A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.

Authors:  M A Trujillo; M J Oneal; S McDonough; R Qin; J C Morris
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

3.  PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.

Authors:  Shuhua Wu; Feifei Wen; Yangyang Li; Xiangqian Gao; Shuang He; Mengyao Liu; Xiangzhi Zhang; Dong Tian
Journal:  Tumour Biol       Date:  2016-01-08

4.  New pancreatic carcinoma model for studying oncolytic adenoviruses in the permissive Syrian hamster.

Authors:  J F Spencer; J E Sagartz; W S M Wold; K Toth
Journal:  Cancer Gene Ther       Date:  2009-05-29       Impact factor: 5.987

Review 5.  Gene therapy in pancreatic cancer.

Authors:  Si-Xue Liu; Zhong-Sheng Xia; Ying-Qiang Zhong
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

6.  Mutation analysis of the EGFR pathway genes, EGFR, RAS, PIK3CA, BRAF, and AKT1, in salivary gland adenoid cystic carcinoma.

Authors:  Kosuke Saida; Takayuki Murase; Mayuko Ito; Kana Fujii; Hisashi Takino; Ayako Masaki; Daisuke Kawakita; Kei Ijichi; Yuichiro Tada; Kimihide Kusafuka; Yoshiyuki Iida; Tetsuro Onitsuka; Yasushi Yatabe; Nobuhiro Hanai; Yasuhisa Hasegawa; Hitomi Shinomiya; Ken-Ichi Nibu; Kazuo Shimozato; Hiroshi Inagaki
Journal:  Oncotarget       Date:  2018-03-30

7.  Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer.

Authors:  Miguel A Trujillo; Michael J Oneal; Julia Davydova; Elizabeth Bergert; Masato Yamamoto; John C Morris
Journal:  Breast Cancer Res       Date:  2009-07-27       Impact factor: 6.466

8.  Progress in gene therapy for prostate cancer.

Authors:  Kamran A Ahmed; Brian J Davis; Torrence M Wilson; Gregory A Wiseman; Mark J Federspiel; John C Morris
Journal:  Front Oncol       Date:  2012-11-19       Impact factor: 6.244

9.  Prognostic significance of K-ras mutations in pancreatic cancer: a meta-analysis.

Authors:  Lian-yuan Tao; Ling-fu Zhang; Dian-rong Xiu; Chun-hui Yuan; Zhao-lai Ma; Bin Jiang
Journal:  World J Surg Oncol       Date:  2016-05-16       Impact factor: 2.754

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.